Mostrar el registro sencillo del ítem
dc.contributor.author | Martínez-Martínez, M. | es_ES |
dc.contributor.author | Rodríguez Berna, Guillermo | es_ES |
dc.contributor.author | Bermejo, Marival | es_ES |
dc.contributor.author | Gonzalez-Alvarez, Isabel | es_ES |
dc.contributor.author | Gonzalez -Alvarez, Marta | es_ES |
dc.contributor.author | Merino, Virginia | es_ES |
dc.date.accessioned | 2020-05-30T03:31:07Z | |
dc.date.available | 2020-05-30T03:31:07Z | |
dc.date.issued | 2019-03 | es_ES |
dc.identifier.issn | 0939-6411 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/144676 | |
dc.description.abstract | [EN] Hydrogels are widely studied as drug delivery system. In this work we propose the employment of tetrakis (hydroxymethyl)phosphonium chloride as crosslinking agent to obtain covalent hydrogels based on chitosan. These hydrogels are obtained by Mannich reaction between the amino groups of chitosan with the hydroxymethyl groups of the crosslinker molecule. They show a pH sensitive second order swelling kinetic, have low toxicity, are biocompatible, mucoadhesive and allow a modified release of the encapsulated drug, camptothecin, for 48 h. This antitumor drug has been studied as a drug of interest to develop oral chemotherapy administration strategies. According to the obtained results, oral administration of camptothecin through hydrogels would provide low concentrations of drug at the absorption site, avoiding carrier saturation and reducing its intestinal toxicity. | es_ES |
dc.description.sponsorship | Authors acknowledge partial financial support to project SAF2016-78756 from MINECO (Spanish Ministry of economy, industry and competitivity). Mayte Martinez-Martínez received a grant from the Ministry of Education and Science of Spain (FPU13-01105). | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.ispartof | European Journal of Pharmaceutics and Biopharmaceutics | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | Camptothecin | es_ES |
dc.subject | Hydrogel | es_ES |
dc.subject | Drug delivery | es_ES |
dc.subject | Oral administration | es_ES |
dc.subject | Chemotherapy | es_ES |
dc.subject | Mucoadhesivity | es_ES |
dc.title | Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1016/j.ejpb.2019.01.009 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MECD//FPU13%2F01105/ES/FPU13%2F01105/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//SAF2016-78756-P/ES/MODELOS IN VITRO DE EVALUACION BIOFARMACEUTICA: BARRERAS BIOLOGICAS Y DISOLUCION BIOPREDICTIVA/ | es_ES |
dc.rights.accessRights | Cerrado | es_ES |
dc.description.bibliographicCitation | Martínez-Martínez, M.; Rodríguez Berna, G.; Bermejo, M.; Gonzalez-Alvarez, I.; Gonzalez -Alvarez, M.; Merino, V. (2019). Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin. European Journal of Pharmaceutics and Biopharmaceutics. 136:174-183. https://doi.org/10.1016/j.ejpb.2019.01.009 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.ejpb.2019.01.009 | es_ES |
dc.description.upvformatpinicio | 174 | es_ES |
dc.description.upvformatpfin | 183 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 136 | es_ES |
dc.identifier.pmid | 30654016 | es_ES |
dc.relation.pasarela | S\404738 | es_ES |
dc.contributor.funder | Ministerio de Educación, Cultura y Deporte | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad | es_ES |